8-K: Crinetics' Oral Paltusotine Achieves Positive Topline Results in Phase 3 Acromegaly Study, Paving Way for NDA Submission

Crinetics Pharmaceuticals announced positive topline results from its Phase 3 PATHFNDR-2 study, demonstrating that oral paltusotine significantly improved IGF-1 levels and acromegaly symptoms compared to placebo.

Summary

• Crinetics Pharmaceuticals has released positive topline results from the PATHFNDR-2 Phase 3 study, which evaluated the efficacy and safety of oral, once-daily paltusotine for treating acromegaly.
• The study involved 111 participants with acromegaly who were not currently on medication.
• The primary endpoint was met with statistical significance (p<0.0001), with 56% of participants on paltusotine achieving an IGF-1 level ≤ 1.0 times the upper limit of normal (xULN) compared to 5% on placebo.
• All secondary endpoints were also met with statistical significance, including a change from baseline in IGF-1 levels, the proportion of participants achieving IGF-1 levels < 1.3 xULN, changes in Acromegaly Symptoms Diary (ASD) scores, and the proportion of participants achieving growth hormone (GH) levels < 1.0 ng/mL.
• Paltusotine was generally well-tolerated, with no serious adverse events reported.
• The company plans to submit a New Drug Application (NDA) to the FDA in the second half of 2024, with a potential launch in 2025.

Sentiment

Score: 9

Explanation: The document conveys a very positive sentiment due to the strong topline results, the achievement of all primary and secondary endpoints, and the planned NDA submission. The lack of serious adverse events further contributes to the positive outlook.

Positives

• Paltusotine demonstrated statistically significant improvements in IGF-1 levels and acromegaly symptoms compared to placebo.
• The drug was generally well-tolerated with no serious adverse events reported.
• The results support the potential for paltusotine to be a new treatment option for acromegaly patients.
• The study results are consistent with the previous PATHFNDR-1 study, reinforcing the efficacy of paltusotine.
• The company is on track to submit an NDA in the second half of 2024, with a potential launch in 2025.

Negatives

• The most commonly reported treatment emergent adverse events (TEAEs) in paltusotine-treated participants included diarrhea, headache, arthralgia, and abdominal pain.
• Some participants experienced mild to moderate adverse events, although the frequency was comparable to the placebo group.

Risks

• Topline results may change following a more comprehensive review of the data.
• The FDA and other regulatory authorities may not agree with the company's interpretation of the results.
• There is a risk of unfavorable new clinical data and further analyses of existing clinical data.
• The commercialization of paltusotine is subject to regulatory approval and market acceptance.
• The company's forward-looking statements are subject to various risks and uncertainties.

Future Outlook

Crinetics plans to submit an NDA for paltusotine in the second half of 2024 and is preparing for a potential launch in 2025. The company also has ongoing clinical studies for other drug candidates and is continuing its discovery efforts for additional endocrine diseases.

Management Comments

• Monica R. Gadelha, M.D., Ph.D., stated that the study demonstrates that paltusotine can provide both symptom control as well as biochemical control in patients who are not currently on pharmacologic treatment.
• Scott Struthers, Ph.D., said that the PATHFNDR-2 results delivered statistically significant topline results across the board and that the totality of data underscores the potential of paltusotine to provide an important new treatment option for all people living with acromegaly.

Industry Context

This announcement is significant as it highlights the potential of an oral, once-daily treatment option for acromegaly, a condition currently managed primarily with injectable medications. This could represent a significant improvement in patient convenience and adherence.

Comparison to Industry Standards

• Current standard treatments for acromegaly often involve monthly injections of somatostatin receptor ligands (SRLs), which can be painful and inconvenient for patients.
• Paltusotine, as an oral, once-daily SRL, aims to address these issues by providing a more convenient and potentially more accessible treatment option.
• The PATHFNDR-2 study results show a significant improvement in IGF-1 levels and symptom control compared to placebo, which is a key benchmark for acromegaly treatments.
• The results are comparable to or better than those seen with injectable SRLs, while offering the advantage of oral administration.
• Companies like Novartis (with Sandostatin and Signifor) and Ipsen (with Somatuline) are key competitors in the acromegaly treatment market, and paltusotine aims to compete with these established injectable therapies.

Stakeholder Impact

• Shareholders are likely to react positively to the strong clinical trial results and the progress towards regulatory approval.
• Patients with acromegaly may benefit from a new, more convenient treatment option.
• Healthcare providers will have a new tool for managing acromegaly.
• Employees of Crinetics are likely to be motivated by the positive results and the potential for commercial success.

Next Steps

• The company plans to submit a New Drug Application (NDA) to the FDA in the second half of 2024.
• The company is actively preparing for a potential 2025 launch of paltusotine.
• The company will continue to analyze the data from the PATHFNDR-2 study.
• The company will continue to develop other drug candidates for endocrine diseases.

Key Dates

Keywords

paltusotine, acromegaly, Phase 3, clinical trial, IGF-1, somatostatin receptor ligand, NDA, endocrine, oral treatment, PATHFNDR-2